Edge Therapeutics (EDGE) Names New COO
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Edge Therapeutics Appoints Chief Operating Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)
October 17, 2016 8:30 AM EDTBERKELEY HEIGHTS, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced the appointment of Daniel Brennan to the newly created position of Chief Operating Officer, effective immediately. Mr. Brennan will be responsible for the pre-commercial planning and market development activities including the health economic assessment of the companys lead product candidate EG-1962, business development activities, and general corporate operations within the company. Mr. Brennan will report to Edges President and Chief... More